Dyslipidaemia development | Pharma intelligence

According to the World Health Organisation, cardiovascular diseases, such as heart attack and stroke, are the leading cause of death globally and account for 30% of all fatalities.1 In the US alone, over 70 million adults are estimated to have high enough cholesterol levels to double their risk of heart disease2; yet numbers of new therapeutics in development for this disease area have lagged behind others such as oncology and neurology. However, an analysis of the current late stage dyslipidaemia landscape reveals that this area may be gaining traction within the industry. A few promising compounds, notably the PCSK9 inhibitors, are working their way through the pipeline, and it looks like a race to develop the next cholesterol blockbuster drug is taking shape. In this paper, we take a forensic look at this area to try to identify current trends and which near-term compounds look the most encouraging.

Highlights in this white paper include:

Although cardiovascular diseases are the leading cause of death globally, the number of new therapeutics in development for this disease area have lagged behind others such as oncology and neurology. However, analysis of the current late stage dyslipidaemia landscape reveals that this area may be gaining traction within the industry. This white paper takes a forensic look at recent developments to identify current trends and which near-term compounds look the most encouraging.

How promising compounds including PCSK9 inhibitors are working their way through the pipeline
The race to develop the next cholesterol blockbuster drug
Phase III pipeline drugs, developers and mechanisms of action
The most commonly reported sponsors of Phase I – III dyslipidaemia trials as reported in Citeline’s clinical trial database, Trialtrove
Breaking down the current set of clinical and preclinical PCSK9 inhibitors by drug type to reveal current anti-PCSK9 strategies